Sculpt

What's in it

The combination logic

The idea is to attack fat loss from more than one direction at once. Tesamorelin targets visceral fat through the growth-hormone system, and Ipamorelin adds a clean pulse on top to help protect muscle without the cortisol swings older GH peptides cause. AOD-9604 works a different way entirely — it acts directly on fat cells without touching the broader hormone system. MOTS-c supports the cellular energy production needed to keep up with all of that metabolic activity. Clinical detail: Tesamorelin is a GHRH analog that stimulates pulsatile endogenous GH release, supporting lipolysis and IGF-1-mediated lean tissue preservation. Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that delivers a cortisol- and prolactin-neutral GH pulse on top of that signal — the two act on different receptors in the same pathway, proposed to produce a more pronounced GH release than either alone. AOD-9604, a modified HGH 176-191 fragment, is proposed to stimulate lipolysis and inhibit lipogenesis via beta-adrenergic receptor activity independent of the GH/IGF-1 axis, avoiding the blood-glucose effects associated with full-length GH. MOTS-c activates AMPK signaling, supporting glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis — proposed to sustain the metabolic throughput the other three components require.

Is there evidence for the combination, or only for the parts? Tesamorelin carries real weight here — it’s FDA-approved (as Egrifta) specifically for reducing visceral fat in a defined patient population, backed by controlled trials showing measurable visceral-fat reduction versus placebo. Ipamorelin, AOD-9604, and MOTS-c each have laboratory or limited human data individually, but no FDA approval. The Tesamorelin-Ipamorelin pairing is a commonly used GH combination in compounded therapy, though that reflects popularity rather than a comparative trial. No study has tested this specific four-peptide combination against its individual components or against any of them alone. The rationale for combining them is mechanistic — four non-overlapping pathways toward the same goal — not the result of a comparative trial.

What it's used for

Overlaps & stacked risks

• Stacking four active peptides means the combined side-effect profile of all four, not a reduced one.
• Growth-hormone-axis peptides (Tesamorelin, Ipamorelin) can affect insulin sensitivity and glucose metabolism.
• Long-term human safety data does not exist for this combination at any dose.
• Injection-site reactions and transient flushing are the most commonly reported effects across the individual components.

Who it is not for

• Pregnant or breastfeeding patients
• Anyone with active malignancy or a history of cancer without physician clearance
• Patients with diabetes or insulin resistance, without close clinician oversight
• Competitive athletes subject to anti-doping testing — growth-hormone secretagogues are prohibited in-competition

Who it suits

Patients pursuing fat loss — particularly visceral fat — who have discussed the limited combination-specific evidence with their provider, have no contraindicating history, and are not competitive athletes subject to testing. Works best alongside, not instead of, diet and training.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine — but it is the difference between a licensed pharmacy working to a standard and an unregulated website. This page describes Sculpt for general educational purposes. It is not medical advice and does not replace a consultation with a licensed provider. Individual results vary, and combination products carry the risks of each included peptide.